American Association of Cancer Research (AACR) Annual Meeting
Phase I/II Study of Dianhydrogalactitol in Patients with Recurrent Malignant Glioblastoma
American Association of Cancer Research (AACR) Annual Meeting
Enhanced in vitro activity of dianhydrogalactitol (VAL-083) in combination with platinum drugs: impact of p53 and platinum-resistance
Society for Neuro-Oncology Poster
Phase I/II Study of Dianhydrogalactitol in Patients with Recurrent Malignant Glioma
AACR New Horizons in Cancer Research Conference: Bringing Cancer Discoveries to Patients
The unique mechanism of action of dianhydrogalactitol (VAL-083) may provide a new treatment option for chemo-resistant cancers
AACR Advances in Pediatric Cancer Research: From Mechanisms and Models to Treatment and Survivorship
Dianhydrogalactitol (VAL-083) Offers Potential Therapeutic Alternatives in the Treatment of Pediatric Brain
2015 Canadian Cancer Research Conference
Exploring the Molecular Mechanisms of Dianhydrogalactitol (VAL-083) in Cancer Treatment
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Dianhydrogalactitol (VAL-083) enhances activity of platinum drugs in non-small cell lung cancer
American Association for Cancer Research (AACR) Advances in Ovarian Cancer Research: Exploiting Vulnerabilities Conference
A comparison of mechanisms and cytotoxic activity of dianhydrogalactitol (VAL-083) to cisplatin in ovarian tumor models harbouring wild-type and mutant p53
16th World Conference on Lung Cancer, Denver, Colorado
Tuesday, September 8, 2015 poster session. Post-Market Clinical Trial of Dianhydrogalactitol in the Treatment of Relapsed or Refractory Non-Small Cell Lung Cancer
GBM2015: 2nd International Symposium on Clinical and Basic Investigation in Glioblastoma in Toledo, Spain
Tuesday, September 8, 2015 poster session. Update on Phase 1/2 study of VAL-083 (dianhydrogalactitol) in patients with recurrent malignant glioma